Orexigen Therapeutics (OREX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Piper Jaffray Lifts PT on Orexigen (OREX) to $21 Following Q2 Results, Says Contrave Gaining Traction
August 6, 2015 10:58 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and raised his price target on Orexigen Therapeutics (NASDAQ: OREX) to $21.00 (from $17.00), noting Contrave is gaining traction, with clouds clearing on commercial efforts.
Duncan commented, "Orexigen reported cash of $76.1M and 2Q15 US sales of Contrave at... More
Orexigen Therapeutics (OREX),Kwang Dong Pharmaceutical Enter Distribution Agreement
August 6, 2015 7:00 AM EDTOrexigen Therapeutics (NASDAQ: OREX) announced that wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd. and Kwang Dong Pharmaceutical Company, Ltd. have executed a distributorship agreement for South Korea for Contrave® (naltrexone HCl / bupropion HCl extended release) monotherapy for weight management in overweight or obese adult... More
Orexigen Therapeutics (OREX), Takeda Enter Amended, Restated Agreement; Resolves All Disputes
August 6, 2015 6:59 AM EDTOrexigen Therapeutics (NASDAQ: OREX) and Takeda Pharmaceutical Company Limited announced execution of an amended and restated collaboration agreement that resolves all outstanding disputes between the companies and aligns the partnership for the continued long-term success of CONTRAVE.
"CONTRAVE has quickly established itself as the... More
